PROTEOSTASIS THERAPEUTICS, INC. (NASDAQ:PTI) Files An 8-K Results of Operations and Financial Condition

PROTEOSTASIS THERAPEUTICS, INC. (NASDAQ:PTI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition

On March14, 2018, Proteostasis Therapeutics, Inc. (the “Company”) expects to disclose the following information in discussions to be held in connection with the Cowen& Co. Annual Healthcare Conference: As of December31, 2017, the Company had approximately $74.5million in cash, cash equivalents and short-term investments, which the Company estimates to be sufficient to fund operations into early 2019. See additional information in the presentation furnished as an exhibit to Item 2.02.

Item 2.02 Regulation FD Disclosure.

On March14, 2018, spokespersons of the Company presented the information in the slides attached hereto as Exhibit 99.1.

The furnishing of the attached presentation slides is not an admission as to the materiality of any information therein. The information contained in the presentation slides is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the U.S. Securities and Exchange Commission, or the SEC, and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the slide titled “Safe Harbor and Disclaimer” in Exhibit 99.1 attached hereto.

The information in this Item 2.02 of this Current Report on Form8-Kand Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the presentation slides attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

Item 2.02 Financial Statements and Exhibits.


EX-99.1 2 d518035dex991.htm EX-99.1 EX-99.1 Proteostasis Therapeutics,…
To view the full exhibit click here


Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.

An ad to help with our costs